Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer Reply

被引：0
|
作者：
Wang, Zhijie [1 ]
Zhao, Zhengyi [2 ]
Wang, Jie [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Clin Res Ctr Canc, Natl Canc Ctr,Canc Hosp,Dept Med Oncol, 17 Pan Jia Yuan South Ln, Beijing 100021, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China
来源：
JAMA ONCOLOGY | 2020年 / 6卷 / 07期
关键词：
D O I：
10.1001/jamaoncol.2020.0646
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1116 / +
页数：2
相关论文
共 50 条
  • [41] Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
    Zhang, Chen
    Yang, Qing
    [J]. FRONTIERS IN ONCOLOGY, 2021, 10
  • [42] Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer
    Rivera, Noelia
    Boada, Aram
    Isabel Bielsa, M.
    Teresa Fernandez-Figueras, M.
    Carcereny, Enric
    Teresa Moran, M.
    Ferrandiz, Carlos
    [J]. JAMA DERMATOLOGY, 2017, 153 (11) : 1162 - 1165
  • [43] PROGRAMMED CELL DEATH-1 INTERACTION WITH PROGRAMMED CELL DEATH LIGAND REGULATES NEURONAL CELL DEATH IN THE MOUSE RETINA
    Gandhi, N. M.
    Sham, C.
    Chen, L.
    Yang, X.
    Sharpe, A. H.
    Freeman, G.
    Braun, J.
    Gordon, L.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (01) : 237 - 237
  • [44] Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Expression in Extranodal NK/T-Cell Lymphoma
    Jung, Ho Young
    Kim, Wook Youn
    Kim, Tae Min
    Heo, Dae Seog
    Kim, Chul-Woo
    Jeon, Yoon Kyung
    [J]. MODERN PATHOLOGY, 2015, 28 : 353A - 353A
  • [45] Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Expression in Extranodal NK/T-Cell Lymphoma
    Jung, Ho Young
    Kim, Wook Youn
    Kim, Tae Min
    Heo, Due Seog
    Kim, Chul-Woo
    Jeon, Yoon Kyung
    [J]. LABORATORY INVESTIGATION, 2015, 95 : 353A - 353A
  • [46] Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer
    Miyashita, Hirotaka
    Mikami, Takahisa
    Satoi, Sera
    Cruz, Christina
    Galsky, Matthew D.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 291 - 298
  • [47] Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1
    Lee, Joo Sang
    Ruppin, Eytan
    [J]. JAMA ONCOLOGY, 2019, 5 (11) : 1614 - 1618
  • [48] Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials
    Huang, Zilu
    Zheng, Shuohan
    Ding, Shirong
    Wei, Yinghong
    Chen, Chen
    Liu, Xing
    Li, He
    Xia, Yunfei
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (03) : 676 - 687
  • [49] Expression of programmed cell death protein 1 and programmed cell death ligand 1 in feline injection site fibrosarcomas
    Mikiewicz, Mateusz
    Pazdzior-Czapula, Katarzyna
    Fiedorowicz, Joanna
    Otrocka-Domaga, Iwona
    [J]. RESEARCH IN VETERINARY SCIENCE, 2024, 176
  • [50] Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
    Jaafar, Jaafar
    Fernandez, Eugenio
    Alwan, Heba
    Philippe, Jacques
    [J]. ENDOCRINE CONNECTIONS, 2018, 7 (05): : R196 - R211
12345